Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 04, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 04, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".